# ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

> **NCT03117816** · PHASE3 · COMPLETED · sponsor: **Philipps University Marburg** · enrollment: 214 (actual)

## Conditions studied

- Chronic Myeloid Leukemia in Remission

## Interventions

- **DRUG:** AOP2014 / Pegylated-Proline-interferon alpha-2b
- **OTHER:** Surveillance

## Key facts

- **NCT ID:** NCT03117816
- **Lead sponsor:** Philipps University Marburg
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-04
- **Primary completion:** 2022-01-26
- **Final completion:** 2022-12-12
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2023-03-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03117816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03117816, "ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03117816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*